Azd9496

Manufactured by Selleck Chemicals

Sourced in United States

AZD9496 is a laboratory product that functions as a selective estrogen receptor downregulator (SERD). It is designed for use in research and development applications.

Automatically generated - may contain errors

Lab products found in correlation

Bazedoxifene, by Selleck Chemicals (1 mentions) Lasofoxifene, by Merck Group (1 mentions) Fulvestrant, by MedChemExpress (1 mentions) Estradiol e2, by Merck Group (1 mentions) Raloxifene, by Bio-Techne (1 mentions) 4 hydroxytamoxifen, by Merck Group (1 mentions) Tamoxifen, by Merck Group (1 mentions) Powershot g10 camera, by Canon (1 mentions) 96 well cell culture cluster, by Corning (1 mentions) Kaempferol, by Merck Group (1 mentions) Herceptin, by Genentech (1 mentions)

3 protocols using azd9496

Comparative Evaluation of Selective ER Modulators

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fulvestrant (CAS No: 129453–61-8, > 99% purity) was purchased from MedChem Express. Estradiol (E2) (E8875), lasofoxifene (SML1026), 4-hydroxy tamoxifen (H7904), and tamoxifen (T5648) were purchased from Sigma. Raloxifene (2280) was purchased from Tocris. GDC-0810 (S7855), bazedoxifene (S2128), and AZD9496 (S8372) were purchased from Selleckchem. GW5638 (5638), GW7604 (7604), and RU 58,668 (RU) were provided by Donald McDonnell (Duke University). G1T48 was provided by G1 Therapeutics, Inc., as analytical grade compound.

Andreano K.J., Wardell S.E., Baker J.G., Desautels T.K., Baldi R., Chao C.A., Heetderks K.A., Bae Y., Xiong R., Tonetti D.A., Gutgesell L.M., Zhao J., Sorrentino J.A., Thompson D.A., Bisi J.E., Strum J.C., Thatcher G.R, & Norris J.D. (2020). G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment, 180(3), 635-646.

+ Open protocol

+ Expand

Synthesis and Procurement of Diverse Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols

SCR-6139, SCR-6515, and SCR-6852 were synthesized as described in (WO2021228210), GDC-9545 was synthesized described in (WO2019245974) (Compound A). AZD9833 was made as described in WO2018077630 (example 17), AZD9496 was purchased from Selleck (#S8372). ARV-471 was synthesized as described in WO2022132652 (compound 1c). Fulvestrant, 4-OH-tamoxifen, Palbociclib, Alpelisib and Elacestrant (RAD1901) were purchased from MCE.

Zhou F., Yang G., Xue L., Liu Y., Guo Y., Zhu J., Yuan L., Gu P., Tang F., Shan J, & Tang R. (2023). SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models. Breast Cancer Research : BCR, 25, 96.

+ Open protocol

+ Expand

Breast Cancer Cell Wound Healing Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Breast cancer cells were plated onto 96-well cell culture clusters (Costar) and grown to confluence, and then serum-starved for 24 h. Herceptin (Genentech, South San Francisco, CA), AZD9496 (AZD; Selleck, Houston, TX, USA) or megestrol acetate (MA; Selleck) were used 60 min before the scratch was made. The monolayer cells were scratched manually with a plastic pipette tip, and after 2 washes with PBS, the wounded cellular monolayer was allowed to heal for 6 h in DMEM containing indicated dose of kaempferol (Sigma, St Louis, MO, USA). Photographs of central wound edges per condition were taken at time 0 h and 6 h using PowerShot G10 camera (Canon, Tokyo, Japan).

Li S., Yan T., Deng R., Jiang X., Xiong H., Wang Y., Yu Q., Wang X., Chen C, & Zhu Y. (2017). Low dose of kaempferol suppresses the migration and invasion of triple-negative breast cancer cells by downregulating the activities of RhoA and Rac1. OncoTargets and therapy, 10, 4809-4819.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!